← Leaderboards
Anne Moscona
Mount Sinai School Of Medicine Of Nyu
$28,223,876
Attributed
$28,223,876
Total exposure
13
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $50.8M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$72,332,528 · 14
By mechanism
U19$49,144,547 · 2
R01$18,045,187 · 5
R21$1,551,696 · 3
R33$1,318,163 · 1
R56$1,300,910 · 2
U54$972,025 · 1
Top collaborators
- Rino Rappuoli1 shared
- Sean P. J. Whelan1 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Curt M Horvath$15,733,450
Others in their field
Top investigators on “Paramyxovirus”
- Thomas William Geisbert · Boston University Medical Campus$29,343,162
- Christopher Broder · Henry M. Jackson Fdn For The Adv Mil/Med$19,756,755
- Benhur Lee · University Of Pennsylvania$18,466,031
- Richard K. Plemper · Georgia State University$17,177,113
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Biao He · Pennsylvania State University-Univ Park$12,966,911
Research focus
ParamyxovirusReceptor BindingViralVirusCell MembranePreventPeptidesInfectionBaseGlycoproteinsMembrane FusionCellsAntiviral AgentsMediatingDesignMolecularLeadIn VivoStructureChimeric ProteinsResistanceVaccinesMembraneIn Vitro
Grant awards (53)
Broad spectrum inhibitors of paramyxovirus envelope proteins$739,596
R01 · FY2025 · AI · contact PI
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2$709,717
R01 · FY2025 · AI · contact PI
Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP$44,108,652
U19 · FY2024 · AI
Prototype strategies for antibodies and vaccines for respiroviruses$5,035,895
U19 · FY2024 · AI · contact PI
Broad spectrum inhibitors of paramyxovirus envelope proteins$780,280
R01 · FY2024 · AI · contact PI
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2$714,282
R01 · FY2024 · AI · contact PI
Broad spectrum inhibitors of paramyxovirus envelope proteins$106,460
R01 · FY2024 · AI · contact PI
Broad spectrum inhibitors of paramyxovirus envelope proteins$41,396
R01 · FY2024 · AI · contact PI
Broad spectrum inhibitors of paramyxovirus envelope proteins$848,745
R01 · FY2023 · AI · contact PI
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2$718,692
R01 · FY2023 · AI · contact PI
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2$722,958
R01 · FY2022 · AI · contact PI
Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2$773,390
R01 · FY2021 · AI · contact PI
Engineering protease-resistant alpha-beta peptides for broad-spectrum antivirals$719,193
R01 · FY2019 · AI · contact PI
Engineering protease-resistant alpha-beta peptides for broad-spectrum antivirals$724,590
R01 · FY2018 · AI · contact PI
Engineering protease-resistant alpha-beta peptides for broad-spectrum antivirals$718,514
R01 · FY2017 · AI · contact PI
Engineering protease-resistant alpha-beta peptides for broad-spectrum antivirals$766,098
R01 · FY2016 · AI · contact PI
Molecular basis for paramyxovirus entry$649,522
R01 · FY2016 · AI · contact PI
Design of CNS-targeted peptide entry inhibitors for emerging henipaviruses$448,632
R33 · FY2016 · AI · contact PI
Engineering protease-resistant alpha-beta peptides for broad-spectrum antivirals$800,168
R01 · FY2015 · AI · contact PI
Molecular basis for paramyxovirus entry$587,667
R01 · FY2015 · AI · contact PI
Design of CNS-targeted peptide entry inhibitors for emerging henipaviruses$434,396
R33 · FY2015 · AI · contact PI
Molecular basis for paramyxovirus entry$549,443
R01 · FY2014 · AI · contact PI
Design of CNS-targeted peptide entry inhibitors for emerging henipaviruses$435,135
R33 · FY2014 · AI · contact PI
Molecular basis for paramyxovirus entry$430,310
R01 · FY2013 · AI · contact PI
A novel antiviral platform: untimely activation of viral fusion mechanisms will$297,417
U54 · FY2013 · AI · contact PI
Design of CNS-targeted peptide entry inhibitors for emerging henipaviruses$218,065
R21 · FY2013 · AI · contact PI
Molecular basis for paramyxovirus entry$522,853
R56 · FY2012 · AI · contact PI
A novel antiviral platform: untimely activation of viral fusion mechanisms will$302,923
U54 · FY2012 · AI · contact PI
Design of CNS-targeted peptide entry inhibitors for emerging henipaviruses$193,625
R21 · FY2012 · AI · contact PI
Molecular basis for paramyxovirus entry$414,092
R01 · FY2011 · AI · contact PI
A novel antiviral platform: untimely activation of viral fusion mechanisms will$371,685
U54 · FY2011 · AI · contact PI
New fusion inhibitors for childhood respiratory viruses, designed to avoid resist$242,798
R21 · FY2011 · AI · contact PI
Molecular basis for paramyxovirus entry$87,632
R01 · FY2011 · AI · contact PI
Design of peptide entry inhibitors and delivery systems to target emerging henipa$755,261
R01 · FY2010 · AI · contact PI
Molecular basis for paramyxovirus entry$418,275
R01 · FY2010 · AI · contact PI
New fusion inhibitors for childhood respiratory viruses, designed to avoid resist$220,250
R21 · FY2010 · AI · contact PI
Molecular basis for paramyxovirus entry$94,640
R01 · FY2010 · AI · contact PI
Design of peptide entry inhibitors and delivery systems to target emerging henipa$772,511
R01 · FY2009 · AI · contact PI
Molecular basis for paramyxovirus entry$422,500
R01 · FY2009 · AI · contact PI
Design of peptide entry inhibitors and delivery systems to target emerging henipa$778,057
R56 · FY2008 · AI · contact PI
Molecular basis for paramyxovirus entry$420,000
R01 · FY2008 · AI · contact PI
Molecular basis for parainfluenza 3 infection$361,613
R01 · FY2007 · AI · contact PI
Molecular basis for parainfluenza 3 infection$372,414
R01 · FY2006 · AI · contact PI
Molecular basis for parainfluenza 3 infection$348,000
R01 · FY2005 · AI
Molecular basis for parainfluenza 3 infection$50,003
R01 · FY2005 · AI
Molecular basis for parainfluenza 3 infection$381,375
R01 · FY2004 · AI
Fusion triggering by Hendra virus F protein: role of G$221,131
R21 · FY2004 · AI
Fusion triggering by Hendra virus F protein: role of G$116,827
R21 · FY2004 · AI
Fusion triggering by Hendra virus F protein: role of G$339,000
R21 · FY2003 · AI
Molecular basis for parainfluenza 3 infection$190,688
R01 · FY2003 · AI
MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION$287,811
R01 · FY2002 · AI
MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION$279,428
R01 · FY2001 · AI
MOLECULAR BASIS FOR PARAINFLUENZA 3 INFECTION$287,923
R01 · FY2000 · AI